Skip to main content
SpringerLink
Log in

Schwerpunkt myeloische Neoplasien

Klassifikation von MPN und chronischen myeloproliferativen Erkrankungen*

  • Schwerpunkt
  • Published:
InFo Hämatologie + Onkologie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

1

© H. H. Kreipe/Springer Medizin; http://doi.org/ddq4

2

© H. H. Kreipe/Springer Medizin; http://doi.org/ddq4

3

© H. H. Kreipe/Springer Medizin; http://doi.org/ddq4

4

© H. H. Kreipe/Springer Medizin; http://doi.org/ddq4

Literatur

  1. Dameshek W et al. Some speculations on the myeloproliferative syndromes. Blood. 1951;6(4):372-5

  2. Thiele J et al. Polycythaemia vera. In: Swerdlow SH et al. (Hrsg) WHO classification of haematopoietic and lymphoid tissues. 2008. IARC Press: Lyon; 40-43

  3. Nowell PC, Hungerford DA. Chromosome studies in human leukemia. II. Chronic granulocytic leukemia. J Natl Cancer Inst. 1961;27:1013-35

  4. Kreipe H. Neoplastische Bildungsstörungen der Hämatopoese mit erhaltener Ausreifung. In: Müller-Hermelink HK, Kreipe HH (Hrsg).Pathologie: Knochenmark, Lymphatisches System, Milz, Thymus. 2018. Springer: Berlin; 47-88

  5. Arber DA et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405

  6. Kreipe et al. Progression of myeloproliferative neoplasms to myelofibrosis and acute leukaemia. J Hematop. 2011;4(2):61-8

  7. Hijiya N et al. Pediatric chronic myeloid leukemia is a unique disease that requires a different approach. Blood. 2016;127(4):392-9

  8. Vardiman JW et al. Chronic myelogenous leukemia, BCR-ABL1 positive. In: Swerdlow SH et al. (Hrsg). WHO classification of haematopoietic and lymphoid tissues. 2008. IARC Press: Lyon; 32-7

  9. Buesche G et al. Marrow fibrosis and its relevance during imatinib treatment of chronic myeloid leukemia. Leukemia. 2007;21(12):2420-7

  10. Bennett JM et al. The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group. Br J Haematol. 1994;87(4):746-54

  11. James C et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-8

  12. Hussein K et al. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis. Exp Hematol. 2009;37(10):1186-1193.e7

  13. Thiele J et al. Primary myelofibrosis. In: Swerdlow SH et al. (Hrsg). WHO classification of haematopoietic and lymphoid tissues. 2008. IARC Press: Lyon; 44-7

  14. Burkhardt R et al. Working classification of chronic myeloproliferative disorders based on histological, haematological, and clinical findings. J Clin Pathol. 1986;39(3):237-52

  15. Georgii A et al. Classification and staging of Ph-negative myeloproliferative disorders by histopathology from bone marrow biopsies. Leuk Lymphoma. 1996;22 Suppl 1:15-29

  16. Buhr T et al. European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis. Haematologica. 2012;97(3):360-5

  17. Campbell PJ et al. Reticulin accumulation in essential thrombocythemia: prognostic significance and relationship to therapy. J Clin Oncol. 2009;27(18):2991-9

  18. Stone RL et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012;366(7):610-8

  19. Buhr T et al. Evolution of myelofibrosis in chronic idiopathic myelofibrosis as evidenced in sequential bone marrow biopsy specimens. Am J Clin Pathol. 2003;119(1):152-8

  20. Bartels S et al. SRSF2 and U2AF1 mutations in primary myelofibrosis are associated with JAK2 and MPL but not calreticulin mutation and may independently reoccur after allogeneic stem cell transplantation. Leukemia. 2015;29(1):253-5

  21. Tefferi A et al. Myeloproliferative neoplasms: A decade of discoveries and treatment advances. Am J Hematol. 2016;91(1):50-8

  22. Klampfl T et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med. 2013;369(25):2379-90

  23. Bartels S et al. Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2. Leukemia. 2018;32(2):556-8

  24. Bartels S et al. Mutations associated with age related clonal hematopoiesis in prefibrotic primary myelofibrosis patients with rapid progression to myelofibrosis. Leukemia. 2019 (im Druck)

  25. Tefferi A et al. U2AF1 mutations in primary myelofibrosis are strongly associated with anemia and thrombocytopenia despite clustering with JAK2V617F and normal karyotype. Leukemia. 2014;28(2):431-3

  26. Thiele J et al. Essential thrombocythaemia. In: Swerdlow SH et al. (Hrsg) WHO classification of haematopoietic and lymphoid tissues. 2008. IARC Press: Lyon; 48-50

  27. Kvasnicka HM, Thiele J. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera. Semin Thromb Hemost. 2006;32(4 Pt 2):362-71

  28. Bain BJ et al. Chronic eosinophilic leukemia, not otherwise specified. In: Swerdlow SH et al. (Hrsg). WHO classification of haematopoietic and lymphoid tissues. 2008. IARC Press: Lyon; 51-3

  29. Bain BJ et al. Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow SH et al. (Hrsg). WHO classification of haematopoietic and lymphoid tissues. 2008. IARC Press: Lyon; 68-73

  30. Cools J et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201-14

Download references

Author information

Authors and Affiliations

  1. Institut für Pathologie, Medizinische Hochschule Hannover,, Hannover, Germany

    Hans Kreipe

Authors
  1. Hans Kreipe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hans Kreipe.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kreipe, H. Klassifikation von MPN und chronischen myeloproliferativen Erkrankungen*. Info Onkol. 22, 12–20 (2019). https://doi.org/10.1007/s15004-019-7237-y

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15004-019-7237-y

Search

Navigation